Carfilzomib modulates tumor microenvironment to potentiate immune checkpoint therapy for cancer

• Published in: EMBO molecular medicine Vol. 14; no. 1; pp. e14502 - n/a
• Main Authors: Zhou, Qian, Liang, Jinxia, Yang, Tong, Liu, Jin, Li, Bo, Li, Yingchang, Fan, Zhenzhen, Wang, Weida, Chen, Wensheng, Yuan, Sujing, Xu, Meng, Xu, Qigui, Luan, Zhidong, Xia, Zhongjun, Zhou, Penghui, Huang, Yadong, Chen, Liang
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 11.01.2022; EMBO Press; John Wiley and Sons Inc; Springer Nature
• Subjects: Animals; Antibodies; Antigen (tumor-associated); Bone marrow; Cancer therapies; Cellular Reprogramming; Cytokines; Drug dosages; EMBO03; EMBO19; Endoribonucleases; Experiments; FDA approval; Humans; Immune checkpoint; Immune Checkpoint Inhibitors - pharmacology; Immune system; immunotherapy; Inhibitor drugs; Kinases; Ligands; Lung cancer; Lung Neoplasms - drug therapy; Lymphocytes; Lymphocytes T; M1 macrophage; M2 macrophage; Macrophages; Mice; Mice, Transgenic; Multiple myeloma; Oligopeptides - pharmacology; Patients; Protein folding; Protein Serine-Threonine Kinases; Proteins; Solid tumors; Targeted cancer therapy; TRAF2 protein; Transgenic animals; Transgenic mice; Tumor cells; Tumor Microenvironment; Tumor necrosis factor-TNF; Tumor-Associated Macrophages - immunology; Tumors; tumor‐associated macrophage; tumor‐associated macrophage; M2 macrophage; tumor microenvironment; M1 macrophage; immunotherapy; tumor-associated macrophage

Impressive clinical benefit is seen in clinic with PD‐1 inhibitors on portion of cancer patients. Yet, there remains an urgent need to develop effective synergizers to expand their clinical application. Tumor‐associated macrophage (TAM), a type of M2‐polarized macrophage, eliminates or suppresses T‐...